India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk. 8 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
The Indian government has decided to fast-track vaccine approvals that have already been authorized by one of four foreign drug regulators or the World Health Organization, clearing the way for the emergency approval for COVID-19 vaccines amid a huge surge in infections and deaths. 14 April 2021
Russian drugmaker Biocad says it has completed one of the stages of development of its new drug, which is designed for the treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 13 April 2021
Russia is accelerating its expansion in the pharmaceutical market of Central and South American states by localization of a number of drugs within their territories, according to recent statements by representatives of some leading Russian drugmakers and pharma analysts, reports The Pharma Letter’s local correspondent. 6 April 2021
Multinational companies (MNCs) must evolve their strategies with a fast-paced China to succeed in the highly competitive market, said company representatives at the two-day 2021 China healthcare investment conference on March 24 in Shanghai. 6 April 2021
Global drugmakers who are trying to minimize their losses from the ever-growing turnover of generics of their original drugs in Russia, have called on the country’s federal government to update the existing register of drugs and patents – in a move to provide them with a better opportunity to protect their patent rights in Russia, according to recent statements by representatives of producers and local media, reports The Pharma Letter’s local correspondent. 30 March 2021
As the call for compulsory licenses on two new tuberculosis (TB) drugs gets louder in India, the Bombay High Court has directed the government to decide on the representations made seeking non-commercial licenses for the two patented life-saving anti TB drugs: bedaquiline and delamanid, which offer fresh hope to multi-drug resistant (MDR) or extensive-drug resistant (XDR) TB patients. 30 March 2021
Russia may face a shortage of some anti-cancer drugs for children, which is mainly due to the suspension of their supplies to the local market by local producers and importers, reports The Pharma Letter’s local correspondent. 23 March 2021
Russian Deputy Prime Minister Tatyana Golikova – a state official also responsible for the development of pharmaceutical and healthcare sector in the Russian government - has instructed the national government to speed the procedure for registration of new drugs in Russia and to provide additional preferences to domestic drugmakers during public procurements, according to recent statements by the state press-service and some local media, reports The Pharma Letter’s local correspondent. 23 March 2021
China has been relying on daily human growth hormone (HGH) injections to treat growth hormone deficiency (GHD), but this is likely to change, if not soon. 19 March 2021
A new strategy for the development of the domestic pharmaceutical sector until 2030 may soon be approved by the Russian government, according to recent statements some senior state officials and local media, reports The Pharma Letter’s local correspondent. 16 March 2021
As India's Biocon Biologics partners pharma giants Novartis and Pfizer to enhance access to life-saving cancer drugs for patients, especially in Sub-Saharan and Asian regions, several Indian drug majors are ponying up to ensure easy access to top cancer drugs, reports The Pharma Letter’s India correspondent. 15 March 2021
For over two decades, the US Food and Drug Administration (FDA) has encouraged the incorporation of patient perspectives into drug development. A major component of the patient perspective is a drug’s effect on Quality of Life (QoL) – a concept that has always been a heterogeneous entity that lacks clear definition. 10 March 2021
The Russian pharmaceutical industry remains heavily dependent on imports of active pharmaceutical ingredients (APIs), despite efforts that have been made by the state to reduce import dependence in recent years, according to recent statements by representatives of some leading Russian pharmaceutical producers and analysts, reports The Pharma Letter’s local correspondent. 8 March 2021
Russian drugmaker Geropharm plans to become one of the leading players in the domestic insulins market within the next several years, with the possible launch of a biosimilar of ultra-long-acting insulin, produced by the Danish diabetes care giant Novo Nordisk, as well as a further expansion of its portfolio. 2 March 2021
An objective to attain self-reliance and reduce import dependence in India's pharmaceutical sector has resulted in the India government clearing 19 applications in a rapid-fire way with a committed investment of $628.84 million under its ambitious production linked incentive (PLI) scheme for the promotion of domestic manufacturing of critical key drug intermediates and active pharmaceutical ingredients (APIs), reports The Pharma Letter’s India correspondent. 1 March 2021
Russia needs a total overhaul of its patent regulation system with regard to pharmaceuticals, with the aim to ensure access for the local population to cheaper drugs, according to recent statements by local pharma analysts and some domestic media, reports The Pharma Letter’s local correspondent. 23 February 2021
Sunday February 28 is Rare Disease Day – a time to review the current orphan drug landscape and the opportunities and challenges presented to the pharmaceutical industry. 22 February 2021
Recent years have seen a growing number of Chinese biotechs doing their clinical studies outside China, reports The Pharma Letter’s local correspondent Wang Fangqing. 17 February 2021
In what is being considered a major fillip to the nation's biotechnology sector, the Indian government has decided to focus on product development commercialization biotech ecosystem in smaller tier-2 and tier-3 towns. A healthy engagement with biotech start-ups is being encouraged across the country, with an aim to take the industry to $150 billion by 2025, reports The Pharma Letter’s India correspondent. 17 February 2021